Key terms

About HCM

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest HCM news

Apr 05 7:00am ET HUTCHMED to Unveil New Cancer Drug Data at AACR 2024 by TipRanks Apr 02 6:59am ET New Hope in Advanced Endometrial Cancer Treatment by TipRanks Apr 02 5:15am ET Hutchmed, Innovent announce fruquintinib and sintilimab NDA accepted by NMPA by TipRanks Mar 28 7:01am ET HUTCHMED’s Savolitinib sNDA Under Review in China by TipRanks Mar 22 6:59am ET HUTCHMED Advances Sovleplenib Trial in China by TipRanks Feb 28 4:55pm ET HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential by TipRanks Feb 06 11:36pm ET Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside by TipRanks Feb 02 9:02am ET Hutchmed licenses IMG-007 and IMG-004 to Inmagene by TipRanks Feb 02 5:13am ET Hutchmed announces Inmagene licenses two drug candidates from the company by TipRanks Jan 30 5:18am ET Hutchmed announces marketing approval of Elunate in Hong Kong by TipRanks Jan 10 7:00pm ET Hutchmed announces NDA acceptance in China for sovleplenib by TipRanks

No recent news articles are available for HCM

No recent press releases are available for HCM

HCM Financials

1-year income & revenue

Key terms

HCM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

HCM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel
JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.
Win McNamee/Getty Images
Jamie Dimon says chance of a bad economy is ‘higher than other people think’